Inactive Instrument

Constellation Pharmaceuticals, Inc.

CNST

US2103731061

Biotechnology & Medical Research

Constellation Pharmaceuticals, Inc.(NasdaqGS:CNST) dropped from S&P Biotechnology Select Industry Index

July 15, 2021 at 12:00 am EDT

Latest news about Constellation Pharmaceuticals, Inc.

MorphoSys Out Licenses Pre-Clinical Oncology Program	22-12-06	CI
MorphoSys : Royalty Pharma Takes Equity Position in MorphoSys for $100 Million	21-07-16	MT
Sector Update: Health Care Stocks Lower Just Ahead of Closing Bell	21-07-15	MT
Sector Update: Health Care Stocks Lacking Much Traction	21-07-15	MT
Constellation Announces Management Changes	21-07-15	CI
Constellation Pharmaceuticals, Inc. Announces Resignation of Jigar Raythatha as Chief Executive Officer	21-07-15	CI
Constellation Pharmaceuticals, Inc. Announces Resignation of Emma Reeve as Chief Financial Officer	21-07-15	CI
DJ Industrial : Wall Street Futures Mostly Lower, Jobless Claims Drop Less Than Expected; Powell Speech Eyed	21-07-15	MT
Sector Update: Health Care Stocks Flat To Lower Pre-Bell Thursday	21-07-15	MT
MorphoSys : Finalizes $1.7 Billion Acquisition of Constellation Pharmaceuticals	21-07-15	MT
MorphoSys : Completes Tender Offer for Constellation Pharmaceuticals	21-07-15	MT
Constellation Pharmaceuticals, Inc.(NasdaqGM:CNST) dropped from NASDAQ Composite Index	21-07-15	CI
Constellation Pharmaceuticals, Inc.(NasdaqGS:CNST) dropped from S&P TMI Index	21-07-15	CI
Constellation Pharmaceuticals, Inc.(NasdaqGS:CNST) dropped from S&P Biotechnology Select Industry Index	21-07-15	CI
Constellation Pharmaceuticals, Inc.(NasdaqGS:CNST) dropped from S&P Global BMI Index	21-07-15	CI
MorphoSys AG completed the acquisition of Constellation Pharmaceuticals, Inc..	21-07-14	CI
Constellation Pharmaceuticals, Inc.(NasdaqGS:CNST) dropped from NASDAQ Biotechnology Index	21-07-14	CI
Constellation Pharmaceuticals, Inc.(NasdaqGS:CNST) dropped from Russell 2000 Growth Index	21-06-25	CI
Constellation Pharmaceuticals, Inc.(NasdaqGS:CNST) added to Russell 2000 Value Index	21-06-25	CI
Constellation Pharmaceuticals, Inc.(NasdaqGS:CNST) dropped from Russell Small Cap Comp Growth Index	21-06-25	CI
Constellation Pharmaceuticals, Inc.(NasdaqGS:CNST) added to Russell 2500 Value Index	21-06-25	CI
Constellation Pharmaceuticals, Inc.(NasdaqGS:CNST) dropped from Russell 3000 Growth Index	21-06-25	CI
Constellation Pharmaceuticals, Inc.(NasdaqGS:CNST) added to Russell 3000 Value Index	21-06-25	CI
Constellation Pharmaceuticals, Inc.(NasdaqGS:CNST) dropped from Russell 2500 Growth Index	21-06-25	CI
Constellation Pharmaceuticals, Inc.(NasdaqGS:CNST) added to Russell 3000E Value Index	21-06-25	CI

Chart Constellation Pharmaceuticals, Inc.

Duration

Period

Chart Constellation Pharmaceuticals, Inc.

More charts

Constellation Pharmaceuticals, Inc. discovers and develops small molecule therapeutics for the treatment of cancer, inflammatory/immunologic disorders and other diseases. The Company has three clinical-stage oncology development programs: the first program is evaluating a compound, CPI-0610, other program is evaluating a compound, CPI-1205 and CPI-0209 is initiate Phase I clinical trial and targeting solid tumors. CPI-1205 is a small molecule designed to promote anti-tumor activity by specifically inhibiting EZH2, an enzyme that suppresses target gene expression. CPI-0610 is a potent and selective small molecule designed to promote anti-tumor activity by selectively inhibiting the function of BET proteins, which are proteins that normally enhance target gene expression. The Company is conducting the ProSTAR trial, which is an open-label Phase Ib/2 clinical trial of CPI-1205 for the treatment of mCRPC in combination with enzalutamide and abiraterone acetate.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-3.00%	102B
REGENERON PHARMACEUTICALS, INC.	+1.97%	96.29B
ARGENX SE	+2.13%	22.18B
BIONTECH SE	-15.40%	21.2B
GENMAB A/S	-9.21%	18.31B
WUXI APPTEC CO., LTD.	-39.98%	17.38B
BEIGENE, LTD.	-15.45%	16.36B
NEUROCRINE BIOSCIENCES, INC.	+4.88%	13.97B
SAREPTA THERAPEUTICS, INC.	+32.45%	12.17B

Bio Therapeutic Drugs